How Eli Lilly Makes its Money: Revenue Breakdown (FY2024)

How Does Eli Lilly Make its Money?

Eli Lilly and Company (NYSE: LLY) generated $45.0 billion in total revenue in fiscal year 2024 — up +32.0% from $34.1B in 2023 — by selling prescription drugs protected by patents and regulatory exclusivity at prices that would be impossible to sustain without them. Lilly is a pharmaceutical company operating the most valuable business model in the health sciences industry: discover a molecule that treats a large, undertreated disease, obtain FDA approval, secure a 15–20 year patent monopoly, and price the drug at whatever the healthcare system will pay.

Eli Lilly’s FY2024 revenue story is almost entirely the story of tirzepatide — a single molecule that Lilly licensed from its own research, developed through a decade of clinical trials, and commercialized as two products: Mounjaro (tirzepatide for Type 2 diabetes, approved May 2022) at $11.6B and Zepbound (tirzepatide for obesity/weight loss, approved November 2023) at $4.9B. Together, tirzepatide generated $16.5B — 37% of total revenue — in what is one of the fastest clinical-to-commercial ramp-ups in pharmaceutical history. This single molecule now makes Eli Lilly the world’s most valuable pharmaceutical company by market capitalization, ahead of Johnson & Johnson, AbbVie, Pfizer, and Merck.

But Eli Lilly is more than one drug. The company also sells Verzenio (abemaciclib, a CDK4/6 breast cancer drug at $4.4B), Taltz (ixekizumab for psoriasis and psoriatic arthritis at $2.9B), Jardiance (empagliflozin for diabetes/heart failure, co-promoted with Boehringer Ingelheim at $2.8B), and a legacy insulin franchise (Humalog/Humulin at $2.3B, in managed decline after Lilly’s voluntary 70% insulin price cut in 2023). The non-tirzepatide portfolio provides revenue stability while the GLP-1 franchise dominates the growth story.

Key Takeaways

• Eli Lilly generated $45.0B in FY2024 revenue (+32% YoY) — the fastest full-year revenue growth ever recorded by a large-cap pharmaceutical company at this scale, driven almost entirely by tirzepatide (Mounjaro + Zepbound) which grew from $5.4B to $16.5B in one year
• Tirzepatide (Mounjaro + Zepbound) = 37% of revenue and growing — both drugs use the same molecule but serve different FDA-approved indications (diabetes vs. obesity); tirzepatide’s dual GIP/GLP-1 receptor agonism mechanism produces superior weight loss (~20.9% body weight reduction) compared to semaglutide-only drugs (Ozempic/Wegovy), Lilly’s primary clinical differentiator
• Demand exceeds supply by a significant margin — Lilly has been capacity-constrained since Zepbound’s launch; the company is investing $18B+ in new manufacturing capacity (Indiana, North Carolina, Ireland, Germany) to close the supply gap; supply constraints have already cost Lilly billions in missed revenue; FDA removed Zepbound from the drug shortage list in late 2024 but supply tightness continues in key doses
• 74% gross margin and 28.7% operating margin — expanding rapidly as the tirzepatide franchise scales; operating margin was 19.1% in 2023 and 28.7% in 2024, a 9.6-point improvement in one year as fixed costs (R&D, manufacturing infrastructure) divide across $11B more in revenue; each incremental dollar of tirzepatide revenue drops at very high operating margins
• $11.5B in R&D spending (25.6% of revenue) — among the highest R&D intensities in pharma; Lilly is betting aggressively on the pipeline: orforglipron (oral GLP-1 for obesity), retatrutide (triple agonist for obesity), donanemab (Alzheimer’s, FDA-approved as Kisunla), and oncology expansions including Verzenio new indications and the acquisition of Morphic Therapeutics (integrin biology) for $3.2B
• Novo Nordisk is the primary competitor — Novo’s semaglutide (Ozempic for diabetes, Wegovy for obesity) competes directly with Lilly’s tirzepatide franchise; the GLP-1 market is large enough for two dominant players, but the companies are engaged in an intense race across clinical superiority, manufacturing scale, payer coverage, and pipeline breadth; together they effectively define the GLP-1 drug market
• Tirzepatide’s patent exclusivity extends into the 2030s — Lilly’s most valuable IP is protected; the first biosimilar entry risk for tirzepatide is not until the mid-2030s; Lilly has 10+ years of protected market leadership which, if the obesity/diabetes market reaches the projected $100B+ annually, represents extraordinary value creation potential

Eli Lilly (LLY) Business Model

Eli Lilly operates the patent-protected blockbuster pharmaceutical model — investing heavily in drug discovery and clinical development over 10–15 years to earn regulatory approval and patent exclusivity that allows above-market pricing for the drug’s protected lifetime. For the manufacturing economics, see the Capital-Intensive Manufacturing Business Model.

The pharmaceutical business model in detail:

Pharmaceutical drug development follows a defined arc: basic research → pre-clinical → Phase 1 (safety, ~80 patients) → Phase 2 (efficacy signal, ~300 patients) → Phase 3 (pivotal trials, ~3,000+ patients) → FDA review → approval → commercial launch → patent expiration → generic/biosimilar entry. The cost from discovery to approval averages $2–3B per approved drug when accounting for failure rates (only ~12% of drugs entering clinical trials eventually receive FDA approval). The payoff for the 12% that succeed: patent-protected pricing that generates billions in revenue with no generic competition for 10–20+ years.

Tirzepatide’s timeline illustrates this model: Lilly began researching GIP/GLP-1 dual agonism in the 2000s, filed patent applications in the 2010s, ran SURPASS (Mounjaro) and SURMOUNT (Zepbound) Phase 3 trials from 2019–2022, received Mounjaro FDA approval in May 2022 and Zepbound approval in November 2023. The 15+ years of investment yielded a molecule generating $16.5B in its second year of full commercial operation. Every other pharmaceutical company that wanted to sell a competing tirzepatide-based drug must wait for Lilly’s patents to expire (mid-2030s) or develop a mechanistically different molecule.

Revenue architecture: branded drug sales + co-promotion agreements:

Pricing and payer dynamics:

Tirzepatide’s list price is approximately $1,069/month for Mounjaro (diabetes) and $1,059/month for Zepbound (obesity). These list prices are not what most patients or payers actually pay — after mandatory rebates to pharmacy benefit managers (PBMs), government programs (Medicaid/Medicare), and insurance negotiations, Lilly receives an “net price” significantly below list. The gap between list price and net price (the “gross-to-net”) for branded drugs commonly runs 40–60%. Lilly’s realized net price per unit is therefore roughly $430–640/month — still extraordinary economics for a drug that costs perhaps $50–100 to manufacture.

Obesity market insurance coverage (the critical expansion lever):

Commercial insurance coverage for Zepbound (obesity indication) has been far lower than for Mounjaro (diabetes indication) because obesity has historically been classified as a lifestyle issue rather than a disease by many insurers. Medicare and most Medicaid programs did not initially cover Zepbound. The Treat and Reduce Obesity Act — if passed — would require Medicare to cover GLP-1 obesity drugs, potentially adding tens of millions of eligible patients. Every percentage point improvement in insurance coverage for obesity (vs. just diabetes) dramatically expands Lilly’s addressable market. This regulatory/coverage dynamic is arguably more important to long-term tirzepatide revenue than any clinical trial result.

Eli Lilly Competitors

GLP-1 / metabolic disease:

• Novo Nordisk — the primary competitor and market co-leader; Novo’s semaglutide franchise (Ozempic for diabetes, Wegovy for obesity, Rybelsus oral for diabetes) generated approximately $21B+ in revenue in 2024; Novo’s head start (Ozempic was approved in 2017 vs. Mounjaro 2022) built insurance coverage, physician prescribing habits, and brand awareness advantages; Lilly’s clinical data showing tirzepatide’s superior weight loss (~20.9% vs. Wegovy’s ~14.9% in head-to-head analyses) is its primary competitive argument; the GLP-1 market is projected to be $100B+ by 2030 — large enough for both companies to grow simultaneously; the key race is manufacturing capacity, pipeline depth (Lilly has retatrutide triple agonist; Novo has oral semaglutide, amycretin), and coverage breadth

Oncology:

• AbbVie — oncology and immunology competitor; AbbVie’s Imbruvica and newer oncology assets compete in adjacent hematology markets; AbbVie’s $21B Humira franchise has begun significant biosimilar erosion, creating a very different revenue trajectory than Lilly’s
• Bristol-Myers Squibb — Opdivo and Yervoy immunotherapy franchise competes broadly in oncology; BMS is not in CDK4/6 inhibitors but competes for oncology prescriber mindshare and payer formulary positions
• Merck — Keytruda immunotherapy competes broadly in oncology; in breast cancer, Merck’s pembrolizumab combinations compete with Verzenio in certain patient segments; Merck has no GLP-1 exposure (a major competitive disadvantage in the current market environment)

Immunology:

• Pfizer — competes in immunology (Xeljanz) and vaccine markets; Pfizer’s post-COVID revenue collapse (Paxlovid/Comirnaty decline) presents a very different financial profile from Lilly; Pfizer is investing heavily in oncology (Seagen acquisition for $43B) and does not yet have a GLP-1 competitive program

Alzheimer’s:

• Biogen — co-developed Leqembi (lecanemab, amyloid-targeting therapy) with Eisai; Leqembi competes directly with Lilly’s Kisunla (donanemab) in the anti-amyloid Alzheimer’s market; the market has been slower to adopt than expected due to infusion requirements, ARIA (brain swelling) monitoring, and modest clinical effect sizes; the two drugs are currently co-existing in a small but growing Alzheimer’s treatment market

See Eli Lilly vs Novo Nordisk for a full head-to-head on the GLP-1 market. For drug distribution dynamics, see Walgreens vs CVS.

Revenue Breakdown

Financial data sourced from Eli Lilly FY2024 Annual Report (10-K).

Tirzepatide (Mounjaro + Zepbound) — $16.5B, 37% of Revenue

Tirzepatide is a first-in-class dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist — the GIP component is Lilly’s key differentiator from Novo Nordisk’s semaglutide (which is GLP-1 only). The dual mechanism produces superior weight loss in clinical head-to-head analyses:

Mounjaro ($11.57B, diabetes): FDA-approved for Type 2 diabetes management. Mounjaro competes with Ozempic (Novo Nordisk) and other injectables in the Type 2 diabetes drug market. The superior HbA1c reduction and weight loss data drove rapid physician adoption among endocrinologists and primary care physicians managing T2D. Mounjaro is now in a strong #1 or #2 market position in most T2D treatment algorithms.

Zepbound ($4.97B, obesity): FDA-approved for chronic weight management (obesity, BMI ≥30 or ≥27 with weight-related comorbidities). The obesity indication represents a dramatically larger addressable market than diabetes — approximately 100M+ adults in the US meet the obesity BMI criteria vs. ~37M with diabetes. Zepbound’s insurance coverage has been the primary commercial constraint: only ~50–60% of commercially insured Americans had Zepbound coverage as of late 2024, with Medicare and most Medicaid excluded. Each coverage expansion event (new employer plans, state Medicaid decisions, potential federal legislation) is a material revenue catalyst.

Manufacturing constraint — the $18B bet: Lilly has invested $18B+ in manufacturing capacity expansion: the LEAP (Lilly’s Expansion of Advanced Pharmaceutical manufacturing) program includes new sites in Lebanon, Indiana; Research Triangle Park, North Carolina; Limerick, Ireland; and Alzey, Germany. Each facility takes 3–5 years to build, qualify, and receive FDA approval. The manufacturing buildout is the single most capital-intensive bet in pharmaceutical industry history. Resolving the supply gap is the biggest near-term revenue upside catalyst — the FDA removed Zepbound from the official drug shortage list in late 2024, but demand continues to outpace supply in certain vial/pen configurations.

Oncology — Verzenio: $4.37B (+26%)

Verzenio (abemaciclib) is a CDK4/6 inhibitor for hormone receptor-positive (HR+), HER2-negative (HER2-) breast cancer — the most common breast cancer subtype. CDK4/6 inhibitors block proteins that drive cancer cell division; combined with endocrine therapy, they significantly extend progression-free survival and overall survival vs. endocrine therapy alone.

Verzenio distinguishes itself from competitors (Pfizer’s Ibrance, Novartis’s Kisqali) through its unique adjuvant (early-stage, non-metastatic) approval, supported by the monarchE trial showing a 35% reduction in invasive disease-free survival events in high-risk early breast cancer. This early-stage expansion dramatically increased Verzenio’s addressable patient population — from approximately 100,000 metastatic patients annually to 250,000+ early-stage high-risk patients. The adjuvant indication continues to drive the +26% growth.

Immunology — Taltz, Olumiant

• Taltz ($2.91B, IL-17A inhibitor): Treats moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. Competes with AbbVie’s Humira, Skyrizi, and Johnson & Johnson’s Stelara/Tremfya. Taltz growth is modest (+3.2%) as the IL-17A class matures and biosimilar Humira pressure reshuffles the immunology market.
• Olumiant ($0.91B, JAK inhibitor, declining): Baricitinib for rheumatoid arthritis. Declining -9% as JAK inhibitor safety label updates (FDA black box warnings for JAK inhibitors as a class) have slowed prescribing; the drug gained emergency use authorization for severe COVID-19 during the pandemic but that demand is gone.

Legacy Diabetes — Insulin Decline

Humalog, Humulin, and Basaglar (biosimilar insulin glargine) are declining as Lilly voluntarily cut U.S. insulin prices by 70% in May 2023 (the single-largest voluntary drug price reduction in pharmaceutical history). The price cut — setting Lilly insulin at a $35/month out-of-pocket cap — was a political and reputational decision driven by intense Congressional pressure and the Inflation Reduction Act’s insulin price cap for Medicare. The financial cost is approximately $300–400M in annual revenue reduction, absorbed by Lilly’s rapidly growing GLP-1 franchise without meaningful impact on overall P&L.

Revenue Trend (3-Year)

The 3-year trend illustrates the tirzepatide ramp with exceptional clarity: in FY2022, Mounjaro launched mid-year and generated $483M (barely a rounding error on a $28B revenue base); in FY2024, tirzepatide generated $16.5B — a 34x increase in two years from one molecule.

The GLP-1 Market Race

The GLP-1/metabolic drug market is the most consequential pharmaceutical market in a generation. The global obesity drug market alone could reach $100–150B annually by 2030 (per Jefferies, Goldman Sachs, and independent analyst estimates) — larger than the current total annual revenue of most pharmaceutical companies. Lilly and Novo Nordisk are engaged in an all-encompassing competition across every dimension:

Clinical differentiation: Lilly’s tirzepatide produces superior weight loss (~20.9% vs. ~14.9% for semaglutide 2.4mg). Novo’s oral semaglutide (Rybelsus, 14mg) gives it an oral formulation advantage in patients who resist injections. Lilly is advancing orforglipron (oral GLP-1, small molecule) in Phase 3 — pending success, orforglipron would be Lilly’s answer to the oral formulation gap while also being patentable in a different way than semaglutide.

Pipeline depth: Lilly’s retatrutide (triple agonist: GIP + GLP-1 + glucagon receptor) showed extraordinary Phase 2 weight loss data (~24% at 48 weeks) — potentially the most potent obesity drug in development. Phase 3 results expected 2025–2026. Novo is advancing amycretin (GLP-1/amylin co-agonist) and has an oral semaglutide 50mg formulation in trials. Both pipelines suggest the competition will intensify rather than settle.

Manufacturing and supply: Both companies are investing tens of billions in manufacturing capacity. Supply has been the primary constraint on both franchises. The company that resolves supply constraints first gains a compounding coverage and prescribing pattern advantage.

Geographic expansion: Both companies are pursuing international coverage expansion. GLP-1 drug uptake in Europe, Japan, China, and emerging markets is significantly below the U.S. — partially due to regulatory timing, partially due to insurance coverage, and partially due to price negotiation with national health systems. International expansion represents a multi-decade growth runway for both.

Eli Lilly (LLY) Income Statement

Financial data sourced from Eli Lilly SEC filings.

Operating income doubled (+98.6%) on 31.9% revenue growth — the clearest illustration of pharmaceutical operating leverage. R&D increased $2.2B but on $10.9B more revenue, the R&D ratio actually fell slightly from 27.3% to 25.5%. Marketing/selling/admin expenses fell -1.8% (absolute dollars) while supporting a +32% revenue increase — the existing commercial infrastructure was able to handle dramatically more volume with minimal incremental cost. Every additional dollar of tirzepatide net revenue beyond the current $16.5B base should drop at 35–45% operating margins — significantly above the current 28.7% blended operating margin.

Eli Lilly (LLY) Key Financial Metrics

• Gross Margin: 74.0% — Premium pharma margins reflecting the pricing power of patent-protected, FDA-approved drugs with no generic competition; tirzepatide’s biologic manufacturing cost (complex peptide synthesis) is higher than small-molecule drugs but still generates 70%+ product-level gross margins; the slight gross margin compression from 2022 (74.8%) reflects tirzepatide’s higher biologic COGS as it becomes a larger share of the mix

• R&D Intensity: 25.5% of Revenue ($11.5B) — Among the highest R&D/revenue ratios in the S&P 500; Lilly is simultaneously funding Mounjaro/Zepbound manufacturing scale, orforglipron Phase 3, retatrutide Phase 3, donanemab/Kisunla commercial launch, Verzenio new indications, and numerous earlier-stage programs including Morphic Therapeutics integrin biology post-acquisition; $11.5B in R&D is roughly 2.2x Lilly’s total FY2022 net income, underscoring the scale of the investment bet

• Operating Leverage — The 9.7-point operating margin expansion (19.0% → 28.7%) in a single year is extraordinary; Lilly’s operating cost structure (R&D labs, manufacturing facilities, sales force) is largely fixed; as tirzepatide revenue grows from $16.5B (2024) to a projected $25B+ (2026E), the fixed cost base does not scale proportionately; each additional $1B of tirzepatide revenue above current run-rate likely produces $350–450M in incremental operating income

• Free Cash Flow — Lilly generated approximately $6–8B in operating cash flow in FY2024 but is investing aggressively in manufacturing capex ($3–5B annually) and acquisitions; net free cash flow (after capex) is substantially positive and growing; the company maintains an investment-grade credit rating and has access to debt markets to fund the $18B manufacturing buildout; Lilly also returned capital to shareholders through its dividend (paid continuously since 1885) and selective share repurchases

• Return on Invested Capital (ROIC) — Pharmaceutical ROIC is driven by the ratio of invested capital in successful drugs vs. capital lost on failed development programs; Lilly’s historical ROIC was moderate (~12–15%) when the portfolio was diversified; as tirzepatide dominates revenue and profits, ROIC is rising sharply; the key risk is that future ROIC is only sustained if the pipeline converts successfully — one bad Phase 3 read-out on a major program doesn’t impair ROIC meaningfully, but a series of failures would

Pipeline: The Next Wave

Lilly’s pipeline represents the company’s claim that the GLP-1 franchise is not a one-product story:

Kisunla (donanemab) — the Alzheimer’s bet: FDA-approved in July 2024 for early symptomatic Alzheimer’s disease, Kisunla represents Lilly’s entry into the amyloid-targeting Alzheimer’s market. Clinical data showed a 35% slowing of cognitive decline in early-stage patients. The commercial barriers are significant: diagnosis requires an amyloid PET scan or CSF test ($3,000–6,000), treatment requires monthly IV infusions at infusion centers, and safety monitoring for ARIA (amyloid-related imaging abnormalities, a form of brain swelling) requires regular MRI monitoring. Medicare has agreed to cover Kisunla with prior authorization. The Alzheimer’s market could be $10B+ annually if commercial infrastructure develops; near-term commercial expectations are modest as infusion center capacity builds.

Is Eli Lilly Profitable?

Yes — Eli Lilly reported net income of $10.59 billion on $45.0B in revenue in FY2024 (net margin: 23.5%). Net income more than doubled year-over-year ($5.24B → $10.59B) entirely driven by tirzepatide operating leverage. Eli Lilly is one of the most profitable companies in the S&P 500 on an absolute dollar basis and has been continuously profitable for decades. The company has paid an uninterrupted quarterly dividend since 1885 (141+ consecutive years). Adjusted (non-GAAP) EPS grew +102% in FY2024 — the largest single-year earnings growth ever reported by Eli Lilly.

The profitability trajectory — not just the current level — is what drives the valuation premium. If tirzepatide grows to $25B+ by 2026 and the operating margin continues expanding toward 35%+, earnings could reach $20B+ annually. At the current ~$740B market cap, this implies a forward P/E of approximately 37x — expensive by historical pharma norms but consistent with a company growing earnings at 50–100% annually.

What to Watch

1. Tirzepatide net revenue (total of Mounjaro + Zepbound) — The single most important metric; management has guided to $58–61B in total 2025 revenue (implying ~$28–30B in tirzepatide); any upside/downside vs. this guidance will be the primary stock catalyst; track quarterly tirzepatide net revenue vs. consensus; supply expansion milestones (new manufacturing site approvals) should be tracked as leading indicators of future tirzepatide revenue capacity

2. Zepbound insurance coverage expansion — Currently ~50–60% commercial coverage; Medicare Part D obesity coverage (if legislative action occurs) would be the largest single coverage expansion event in the drug’s history; track any Congressional action on the Treat and Reduce Obesity Act and any major employer plan decisions to add or drop GLP-1 obesity coverage; each 10-point coverage expansion roughly correlates to $1–2B in additional addressable prescription volume

3. Orforglipron Phase 3 readout — An oral, small-molecule GLP-1 agonist would be a category-defining achievement: no injection required, simpler manufacturing (small molecule vs. biologic), potentially lower COGS, mass market accessibility; Phase 3 data expected 2025; success would open GLP-1 therapy to the global population that refuses injectable medications; failure would be a moderate setback for Lilly but not existential (tirzepatide injectable remains the anchor)

4. Retatrutide Phase 3 data — If triple agonist (GIP/GLP-1/Glucagon) Phase 3 confirms the ~24% Phase 2 weight loss and the safety profile holds, retatrutide would become the most efficacious obesity drug ever approved; Phase 3 readouts expected 2025–2026; potential approval 2026–2027; success would further separate Lilly from Novo Nordisk on weight loss efficacy

5. Kisunla (donanemab) commercial ramp — Alzheimer’s treatment adoption is a 3–5 year commercial build, not a launch-quarter event; track quarterly prescriptions, infusion center expansion, Medicare Part B reimbursement rates, and ARIA management protocol adoption; the drug’s commercial success depends on the healthcare system’s ability to build the diagnostic and monitoring infrastructure that donanemab requires

6. Manufacturing capacity utilization and supply indicators — Track any FDA observations at new manufacturing sites (Warning Letters would delay capacity additions), Lilly management commentary on supply constraints, and any changes to the FDA shortage database for Zepbound; the $18B capex commitment is the highest-stakes operational execution challenge in Lilly’s history; delays in manufacturing qualification directly translate to delayed revenue

Eli Lilly (LLY) Financial Summary

Eli Lilly (NYSE: LLY) generated $45.0 billion in revenue in fiscal year 2024 (+31.9%), earning $10.6 billion in net income (23.5% net margin) with a 74.0% gross margin and 28.7% operating margin — one of the most profitable years ever recorded by a U.S. pharmaceutical company. The tirzepatide franchise (Mounjaro + Zepbound) at $16.5B represents one of the fastest drug commercialization ramps in pharmaceutical history, and operating leverage as the franchise scales is driving rapid margin expansion. The company’s $11.5B annual R&D spend funds the next wave: orforglipron (oral GLP-1), retatrutide (triple agonist), new tirzepatide indications (sleep apnea, heart failure, NASH), and Kisunla for Alzheimer’s. Key risks: Novo Nordisk competition, manufacturing execution on the $18B buildout, insurance coverage dynamics for obesity indications, and the long-term patent cliff (tirzepatide exclusivity mid-2030s). Compared to Pfizer and Merck, Lilly’s GLP-1 franchise gives it a uniquely concentrated, high-growth revenue driver in the most promising drug market of the 2020s–2030s. See the Pharmaceuticals Sector for full industry context, and Eli Lilly vs Novo Nordisk for the GLP-1 market head-to-head.